Reduction of febrile neutropenia by using long-acting granulocyte colony-stimulating factors in patients with solid tumors receiving every-2-week chemotherapy

Neutropenia is a common hematological complication of chemotherapy (СT). The number of studies showed that the underperformance of the treatment program due to the development of this type of hematological toxicity could lead to the decrease in therapy efficacy and to the increase in cancer mortalit...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	I. B. Kononenko, A. V. Snegovoy, O. P. Grebennikova, V. Yu. Sel’chuk, O. V. Palchinskaia
Formato:	article
Lenguaje:	RU
Publicado:	IP Habib O.N. 2020
Materias:	neutropenia febrile neutropenia granulocyte colony-stimulating factors colorectal cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/469aaf7ad53a4eb68ac0c3fdb3d1244c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:469aaf7ad53a4eb68ac0c3fdb3d1244c
record_format	dspace
spelling	oai:doaj.org-article:469aaf7ad53a4eb68ac0c3fdb3d1244c2021-11-30T17:03:34ZReduction of febrile neutropenia by using long-acting granulocyte colony-stimulating factors in patients with solid tumors receiving every-2-week chemotherapy1815-14341815-144210.26442/18151434.2020.3.200279https://doaj.org/article/469aaf7ad53a4eb68ac0c3fdb3d1244c2020-11-01T00:00:00Zhttps://modernonco.orscience.ru/1815-1434/article/viewFile/52598/36043https://doaj.org/toc/1815-1434https://doaj.org/toc/1815-1442Neutropenia is a common hematological complication of chemotherapy (СT). The number of studies showed that the underperformance of the treatment program due to the development of this type of hematological toxicity could lead to the decrease in therapy efficacy and to the increase in cancer mortality. Infections that occur as a result of prolonged neutropenia are extremely dangerous. The most severe manifestation of grade 4 neutropenia is febrile neutropenia (FN), which can lead to death from severe infections. Such patients should be immediately hospitalized and should receive empirical therapy with broad-spectrum antibiotics. The costs, associated with the hospitalization, due to FN increase total cost of cancer patients treatment. The application of recombinant forms of the natural protein granulocyte colony-stimulating factor (G-CSF) in clinical practice has solved the number of important problems on that front. The clinical studies and common use show that primary and secondary prevention using recombinant G-CSF reduces the risk of FN development and improves the results of the treatment of malignancies. The review provides actual data concerning pharmacological properties, clinical efficacy and reasonable use of G-CSF with prolonged action to prevent FN in patients with solid tumors during 2-week CT cycles. Special attention is paid to CH regimens with the inclusion of 5-fluorouracil, oxaliplatin, irinotecan in the treatment of colorectal cancer (CRC). The use of neoadjuvant treatment in such patients allows to achieve resectability of the tumor and to perform radical surgery. The maintenance of drugs dose intensity throughout the cycle of CT plays an important role in achieving the treatment success. Therefore, the prevention of CT-induced severe neutropenia and FN is especially important in patients who are the candidates for surgical treatment. The results of some studies confirm the necessity of using G-CSF with prolonged action during 2-week CT cycles in patients with CRC.I. B. KononenkoA. V. SnegovoyO. P. GrebennikovaV. Yu. Sel’chukO. V. PalchinskaiaIP Habib O.N.articleneutropeniafebrile neutropeniagranulocyte colony-stimulating factorscolorectal cancerNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282RUСовременная онкология, Vol 22, Iss 3, Pp 133-141 (2020)
institution	DOAJ
collection	DOAJ
language	RU
topic	neutropenia febrile neutropenia granulocyte colony-stimulating factors colorectal cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	neutropenia febrile neutropenia granulocyte colony-stimulating factors colorectal cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 I. B. Kononenko A. V. Snegovoy O. P. Grebennikova V. Yu. Sel’chuk O. V. Palchinskaia Reduction of febrile neutropenia by using long-acting granulocyte colony-stimulating factors in patients with solid tumors receiving every-2-week chemotherapy
description	Neutropenia is a common hematological complication of chemotherapy (СT). The number of studies showed that the underperformance of the treatment program due to the development of this type of hematological toxicity could lead to the decrease in therapy efficacy and to the increase in cancer mortality. Infections that occur as a result of prolonged neutropenia are extremely dangerous. The most severe manifestation of grade 4 neutropenia is febrile neutropenia (FN), which can lead to death from severe infections. Such patients should be immediately hospitalized and should receive empirical therapy with broad-spectrum antibiotics. The costs, associated with the hospitalization, due to FN increase total cost of cancer patients treatment. The application of recombinant forms of the natural protein granulocyte colony-stimulating factor (G-CSF) in clinical practice has solved the number of important problems on that front. The clinical studies and common use show that primary and secondary prevention using recombinant G-CSF reduces the risk of FN development and improves the results of the treatment of malignancies. The review provides actual data concerning pharmacological properties, clinical efficacy and reasonable use of G-CSF with prolonged action to prevent FN in patients with solid tumors during 2-week CT cycles. Special attention is paid to CH regimens with the inclusion of 5-fluorouracil, oxaliplatin, irinotecan in the treatment of colorectal cancer (CRC). The use of neoadjuvant treatment in such patients allows to achieve resectability of the tumor and to perform radical surgery. The maintenance of drugs dose intensity throughout the cycle of CT plays an important role in achieving the treatment success. Therefore, the prevention of CT-induced severe neutropenia and FN is especially important in patients who are the candidates for surgical treatment. The results of some studies confirm the necessity of using G-CSF with prolonged action during 2-week CT cycles in patients with CRC.
format	article
author	I. B. Kononenko A. V. Snegovoy O. P. Grebennikova V. Yu. Sel’chuk O. V. Palchinskaia
author_facet	I. B. Kononenko A. V. Snegovoy O. P. Grebennikova V. Yu. Sel’chuk O. V. Palchinskaia
author_sort	I. B. Kononenko
title	Reduction of febrile neutropenia by using long-acting granulocyte colony-stimulating factors in patients with solid tumors receiving every-2-week chemotherapy
title_short	Reduction of febrile neutropenia by using long-acting granulocyte colony-stimulating factors in patients with solid tumors receiving every-2-week chemotherapy
title_full	Reduction of febrile neutropenia by using long-acting granulocyte colony-stimulating factors in patients with solid tumors receiving every-2-week chemotherapy
title_fullStr	Reduction of febrile neutropenia by using long-acting granulocyte colony-stimulating factors in patients with solid tumors receiving every-2-week chemotherapy
title_full_unstemmed	Reduction of febrile neutropenia by using long-acting granulocyte colony-stimulating factors in patients with solid tumors receiving every-2-week chemotherapy
title_sort	reduction of febrile neutropenia by using long-acting granulocyte colony-stimulating factors in patients with solid tumors receiving every-2-week chemotherapy
publisher	IP Habib O.N.
publishDate	2020
url	https://doaj.org/article/469aaf7ad53a4eb68ac0c3fdb3d1244c
work_keys_str_mv	AT ibkononenko reductionoffebrileneutropeniabyusinglongactinggranulocytecolonystimulatingfactorsinpatientswithsolidtumorsreceivingevery2weekchemotherapy AT avsnegovoy reductionoffebrileneutropeniabyusinglongactinggranulocytecolonystimulatingfactorsinpatientswithsolidtumorsreceivingevery2weekchemotherapy AT opgrebennikova reductionoffebrileneutropeniabyusinglongactinggranulocytecolonystimulatingfactorsinpatientswithsolidtumorsreceivingevery2weekchemotherapy AT vyuselchuk reductionoffebrileneutropeniabyusinglongactinggranulocytecolonystimulatingfactorsinpatientswithsolidtumorsreceivingevery2weekchemotherapy AT ovpalchinskaia reductionoffebrileneutropeniabyusinglongactinggranulocytecolonystimulatingfactorsinpatientswithsolidtumorsreceivingevery2weekchemotherapy
_version_	1718406374806781952

Reduction of febrile neutropenia by using long-acting granulocyte colony-stimulating factors in patients with solid tumors receiving every-2-week chemotherapy

Ejemplares similares